STOCK TITAN

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Immutep (IMMP) reported 81.1% disease-free survival at 12 months in its Phase II EFTISARC-NEO trial for high-risk, resectable soft tissue sarcoma. The study tested eftilagimod alfa with pembrolizumab and radiotherapy before surgery. Of 40 enrolled patients, 38 underwent surgery and were evaluated for survival; eight had disease recurrence by April 30, 2026. The 18-month disease-free survival estimate was also 81.1% but remains immature.

The trial previously met its primary endpoint, with median tumour hyalinisation and fibrosis, changes in tumour tissue, of 51.5%. Exploratory analyses linked higher immune-cell levels in tumours and greater tissue changes after treatment to higher 12-month disease-free survival. Immutep expects more data in CY2027 and targets an H2 CY2027 start for a trial intended to support regulatory approval, subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources.

Loading...
Loading translation...
8 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointPrimary endpoint was met, with median tumour hyalinisation and fibrosis of 51.5% after treatment.
  • Moderate point12-month disease-free survival was 81.1% in the Phase II survival analysis.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Trial intended to support regulatory approval is in preparation, with Immutep targeting initiation in H2 CY2027.
  • Minor point12-month local recurrence-free survival was 94.1%.
  • Minor point12-month distant metastasis-free survival was 86.2%.
3 minor points
  • Minor pointHigher post-treatment tumour lymphocyte levels showed exploratory 12-month disease-free survival of 95.0% above 310 cells/mm² versus 64.9% at lower levels.
  • Minor pointGreater treatment-related hyalinisation and fibrosis showed exploratory 12-month disease-free survival of 93.8% above 52% versus 71.4% at lower levels.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional EFTISARC-NEO data are expected by Immutep in CY2027.

Negative

  • Minor point18-month disease-free survival estimate of 81.1% remains immature, with follow-up ongoing.
  • Minor pointDisease recurrence occurred in eight of 38 patients evaluated after surgery by April 30, 2026.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Planned trial start depends on regulatory interactions, manufacturing timelines, partnering arrangements and available resources.

News Explained

At its CTOS 2026 poster, Immutep reported exploratory subgroup results: 12-month DFS was 95.0% versus 64.9% for patients above versus at lower levels than 310 TIL cells/mm², and 93.8% versus 71.4% for patients with treatment-related hyalinisation and fibrosis above 52% versus at lower levels.

Key Figures

12-month disease-free survival: 81.1% 18-month disease-free survival: 81.1% 12-month local recurrence-free survival: 94.1% +4 more
12-month disease-free survival
81.1%
Latest analysis; mature
18-month disease-free survival
81.1%
Kaplan-Meier estimate; immature
12-month local recurrence-free survival
94.1%
EFTISARC-NEO latest analysis
12-month distant metastasis-free survival
86.2%
EFTISARC-NEO latest analysis
12-month DFS by post-treatment TIL level
95.0% vs. 64.9%
TIL levels above 310 cells/mm² vs. lower levels
12-month DFS by hyalinisation and fibrosis
93.8% vs. 71.4%
Above 52% vs. lower levels
Patients evaluated for survival
38 patients
Patients who underwent surgery

Previous Clinical trial Reports

1 past event · Latest: Oct 23
Same Type 1 event
  1. Oct 23

    EFTISARC-NEO QoL data

    24h Move
    +0.9%

    Earlier report showed improved quality of life after surgery and a 51.5% median tumour hyalinisation/fibrosis result.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

disease-free survival, tumour-infiltrating lymphocytes, kaplan-meier estimate, neoadjuvant, +1 more
5 terms
disease-free survival medical
"12-month disease-free survival (mature) | 81.1%"
Disease-free survival measures the length of time after treatment during which a patient shows no signs or symptoms of the disease. For investors, it is a key clinical result because longer disease-free periods suggest a therapy is effective at preventing recurrence, which can drive regulatory approval, market demand and revenue potential—think of it as how long a repaired item runs without breaking down.
tumour-infiltrating lymphocytes medical
"higher levels of tumour-infiltrating lymphocytes (TILs)"
Immune cells, mainly T lymphocytes, that have migrated from the blood into a solid tumour and are found among or next to the cancer cells; they show whether the body's immune system is recognising the tumour and can include various subtypes with different roles. Clinically, tumour-infiltrating lymphocytes (TILs) can be analysed to assess tumour-immune interaction and can be isolated, expanded outside the body and given back to a patient as a form of adoptive cell therapy, but their presence and activity vary widely between tumours and patients.
kaplan-meier estimate medical
"The current Kaplan-Meier estimate at 18 months"
A Kaplan-Meier estimate is a statistical curve that shows how the chance of avoiding a particular event (like disease progression, treatment failure, or death) changes over time among a group of people in a clinical study. Think of it like a chart tracking how many lightbulbs remain working as hours pass; for investors it matters because it summarizes a drug or treatment’s durability and timing of benefits, which can influence regulatory decisions, market expectations, and valuation.
neoadjuvant medical
"advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma"
"Neoadjuvant" describes treatments or interventions that are given before the main or primary procedure, such as surgery or a major decision. It’s like preparing the ground before planting seeds, aiming to improve the final outcome. For investors, understanding neoadjuvant approaches can provide insight into how companies enhance results or effectiveness in their processes or products.
orphan drug designation regulatory
"and Orphan Drug Designation in soft tissue sarcoma"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of 81.1% in patients with resectable soft tissue sarcoma.
  • Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels.
  • Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels.
  • Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy.

SYDNEY, AUSTRALIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announced new data from the investigator-initiated EFTISARC-NEO Phase II study presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster number P 448).

The study is evaluating Immutep’s eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma. Forty patients were enrolled, and 38 patients underwent surgery and were included in the survival evaluation.

The latest analysis currently shows a disease-free survival (DFS) of 81.1% at 12 months. The current Kaplan-Meier estimate at 18 months is also 81.1%, although this later time point remains immature, and follow-up is ongoing. Among the 38 patients who underwent surgery and were evaluated, eight patients had experienced disease recurrence at the data cut-off (April 30, 2026).

Table 1 – Survival results for soft tissue sarcoma patients from EFTISARC-NEO

OutcomeLatest Analysis
12-month disease-free survival (mature)81.1%
18-month disease-free survival (immature)81.1%
12-month local recurrence-free survival94.1%
12-month distant metastasis-free survival86.2%
Median follow-up19.1 months


In addition, exploratory analyses showed that higher levels of tumour-infiltrating lymphocytes (TILs) and greater hyalinisation and fibrosis after treatment may be associated with better DFS. In particular, patients with post-treatment TIL levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels. Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels of hyalinisation and fibrosis. The presence of tertiary lymphoid structures (TLS) and baseline expression of PD-L1, LAG-3 and TIGIT did not correlate with survival outcomes.

These survival and exploratory findings build on previously reported EFTISARC-NEO results in which the trial met its primary endpoint with a median tumour hyalinisation/fibrosis of 51.5% following neoadjuvant therapy with efti, pembrolizumab and radiotherapy. The new data are consistent with efti's mechanism of action, in which activation of antigen-presenting cells drives a stronger anti-tumour T cell response, and suggest that a stronger immune response in the tumour may be associated with improved patient survival outcomes.

Pawel Sobczuk, MD PhD, one of the Principal Investigators of EFTISARC-NEO, said: “These results are highly encouraging for patients with high-risk soft tissue sarcoma, where recurrence remains a major concern despite surgery and radiotherapy. Disease-free survival of approximately 81% maintained through 12 months and on a preliminary basis also at 18 months is an important observation, and the association between a strong immune response in the tumour and better disease-free survival is particularly compelling. Together with the substantial pathological responses previously reported, the findings reinforce the potential of this novel neoadjuvant approach and provide a strong rationale for continued follow-up and further clinical evaluation.”

Marc Voigt, CEO of Immutep, said: “With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture. The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response. We believe these results strengthen the rationale for further potential clinical development in this indication, where patients remain in need of more effective treatment options.”

The poster is available on the Posters & Publications page of Immutep’s website.

Next Steps

Immutep anticipates reporting additional data from EFTISARC-NEO in CY2027.

Subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources, the Company is preparing to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in H2 CY2027.

About EFTISARC-NEO

EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti.

The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).

About Eftilagimod Alfa (efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What disease-free survival did Immutep report in the EFTISARC-NEO trial?

EFTISARC-NEO reported 81.1% disease-free survival at 12 months among patients evaluated after surgery. The 18-month estimate was also 81.1%, but remains immature and follow-up is ongoing. Median follow-up was 19.1 months.

Which tumour findings were linked to better survival in Immutep’s EFTISARC-NEO trial?

Exploratory analyses linked higher 12-month disease-free survival to more immune cells in tumours and greater tumour tissue changes after treatment. Survival was 95.0% above 310 tumour-infiltrating lymphocytes per mm² versus 64.9% at lower levels, and 93.8% with hyalinisation and fibrosis above 52% versus 71.4% at lower levels.

When could Immutep start the next efti trial in soft tissue sarcoma?

Immutep is targeting initiation in H2 CY2027 for a trial of efti before surgery intended to support regulatory approval. The timing depends on regulatory interactions, manufacturing timelines, partnering arrangements and available resources.

Who is running and funding Immutep’s EFTISARC-NEO trial?

The Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw leads the trial. A grant from the Polish Medical Research Agency provides most of the funding, and Immutep supplies efti.

Keep reading